Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00481832|
Recruitment Status : Terminated (Accrual Factor)
First Posted : June 4, 2007
Results First Posted : February 14, 2018
Last Update Posted : February 14, 2018
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma, Non-Hodgkin||Drug: Cyclophosphamide Drug: BCNU Drug: Etoposide Drug: Filgrastim Drug: Antithymocyte globulin Drug: Cyclosporine Drug: Mycophenolate mofetil Drug: Rituximab Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT) Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) Procedure: Total lymphoid irradiation Drug: CD34+ Cells Drug: Solu-Medrol||Phase 2|
Currently, patients with recurrent or primary refractory non-Hodgkin's lymphoma are treated with second-line chemotherapy (usually 2-3 courses) for the purpose of cytoreduction and to establish sensitivity to chemotherapy. Thereafter, peripheral blood progenitor cells are mobilized with cyclophosphamide and granulocyte colony stimulating factor, apheresed and cryopreserved. The standard high dose regimen consists of augmented carmustine, etoposide and cyclophosphamide. Unfortunately, there are subgroups of patients with poor outcomes using autologous transplantation including those with transformed lymphoma as well as patients who do not attain a minimal disease state due to chemoresistant disease.
These groups of patients have limited disease control and survival with standard chemotherapy regimens, and although they often have excellent cytoreduction with the high-dose chemotherapy regimen, relapse remains the primary cause of treatment failure. The current trial utilizes a similar approach that has been taken with patients with multiple myeloma, who appear to benefit from an allogeneic graft-versus-tumor effect, using a combined autologous and non-myeloablative allogeneic transplant regimen to reduce transplant-related complications. Eligible patients will be treated with high-dose chemotherapy using BCNU, etoposide and cyclophosphamide with autologous hematopoietic cell support as a method of cytoreduction. Approximately 60-120 days after the autologous transplant, patients will receive an allogeneic transplant using a preparative regimen of total lymphoid irradiation and anti-thymocyte globulin in an attempt to develop a graft-versus-lymphoma effect.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma|
|Study Start Date :||January 2007|
|Actual Primary Completion Date :||October 27, 2014|
|Actual Study Completion Date :||March 30, 2017|
Experimental: T & B Cell Mobilization Auto & Allo HCT
A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.
4 gm /m² IV over 2 hours on day 8
The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:
Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)
60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
Drug: Antithymocyte globulin
1.5 mg/kg/d, IV from day -11 to -7
Other Name: ATG
5mg/kgbid,variable, po or IV
Drug: Mycophenolate mofetil
15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
Other Name: Autologous peripheral blood progenitor cell (PBPC) transplantation
Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
Other Name: Allogeneic peripheral blood progenitor cell (PBPC) transplantation
Procedure: Total lymphoid irradiation
TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
Other Name: TLI
Drug: CD34+ Cells
2 x 10e6 CD34+ cells per kg actual body weight on Day 0
1 mg/kg, Day-11 to Day-7
Other Name: Methylprednisolone
- Event-free Survival (EFS) [ Time Frame: 3 years ]
Event-free survival (EFS) as determined for participants who receive both planned transplants, for a minimum of 3 years.
Events are defined as "disease progression/relapse" and "death of all causes".
- Incidence of Chemotherapy-associated Pneumonitis [ Time Frame: 3 years ]Interstitial pneumonitis (IP) is a risk associated with high-dose carmustine (BCNU) or other chemotherapy drugs used for transplantation. IP is diagnosed by 1) a decrease of >25% in DLCO compared with pre-transplant PFT DLCO values or 2) a drop of 7% or more in oxygen saturation after exertion.
- Relapse Rate [ Time Frame: 3 years ]Relapse rate (disease recurrence) 3 years after transplant, for participants who received both transplants, as determined by Kaplan-Meier estimation.
- Overall Survival (OS) [ Time Frame: 3 years ]Overall Survival (OS) 3 years after transplant, for participants who received both transplants, as determined by Kaplan-Meier estimation.
- Incidence of Acute Graft Versus Host Disease (GvHD) [ Time Frame: 6 Months ]The development of GvHD in vaccinated patients of any grade and at 6 months.
- Incidence of Chronic Graft Versus Host Disease (GvHD) [ Time Frame: 3 years ]The development of GvHD in vaccinated patients of any grade at 6 months.
- Overall Mortality Rate [ Time Frame: 3 years ]Overall mortality is determined by Kaplan-Meier estimation. The overall morality rate is expressed as the percentage of patients who died for any reason, including disease-related death.
- Median Time to Neutrophile Engraftment [ Time Frame: up to 45 days ]Complete blood counts were measured daily after allogeneic transplant. Time to neutrophil engraftment is defined as the number of days it takes to reach an absolute neutrophils count (ANC) >500, counting from the day of transplant.
- Achieving Full Donor Chimerism [ Time Frame: Up to 1 year ]Achieving full donor chimerism (donor T cells >95%): Blood was sent for donor cell percentage measured by short tandem repeat (STR) at post-transplant Day 30; Day 60; Day 90; Day 120; Day 180; Day 270; and Day 360. Full donor chimerism is defined as donor CD3+ cells > 95%.
- Median Time to Platelet Engraftment [ Time Frame: Up to 45 days ]Complete blood counts were measured daily after allogeneic transplant. Time to platelet engraftment is defined as the number of days it takes to reach platelet count >20,000, counting from the day of transplant.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age 18 to 70 years.
- Histologically proven non-Hodgkin's lymphoma
- Relapse after achieving initial remission or failure to achieve initial remission.
- KPS > 70%
- Matched related or unrelated donor identified and available. Donor must be a complete match or have only a single allele mismatch.
- Recent Bone marrow biopsy and cytogenetic analysis
- Patients must have a pretreatment serum bilirubin < 2 x the institutional ULN, a serum creatinine < 2 x the institutional ULN and measured or estimated creatinine clearance > 50 cc/min by the following formula (all tests must be performed within 28 days prior to mobilization ): Estimated Creatinine Clearance = (140 age) X WT(kg) X 0.85 if female 72 X serum creatinine(mg/dl).
- Patients must have an EKG within 42 days prior to registration that shows no significant abnormalities that are suggestive of active cardiac disease.
- Patients must have an echocardiogram or MUGA scan within 42 days of registration. If the ejection fraction is < 40%, the patient will not be eligible. If the ejection fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echo with a normal response to exercise.
- Patients must have a corrected diffusion capacity > 50% prior to the autologous transplant and > 40% prior to the allogeneic transplant.
- Patients with known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible.
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
- Pregnant or breast-feeding women are ineligible due to the known birth defects association with the treatments used in this study.
- Patients known to be human immunodeficiency virus (HIV)-positive are ineligible because the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population.
- Patients with prior maligancies diagnosed > 5 years ago without evidence of disease are eligible. Patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible.
- Patients with uncontrolled infection.
- No prior autologous or allogeneic hematopoietic cell transplantation.
- Related or unrelated HLA identical donors who are in good health and have no contra-indication to donation.
- No contra-indication for the donor to collection by apheresis of mononuclear cells mobilized by G-CSF at a dose of 16 µg/kg of body weight.
- Virology testing including CMV, HIV, EBV, HTLV, RPR, Hepatitis A, B and C will be performed within 30 days of donation.
- No prior malignancy is allowed except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the donor has been disease-free for five years
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00481832
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Wen-Kai Weng||Stanford University|
|Responsible Party:||Wen-Kai Weng, Associate Professor of Medicine, Stanford University|
|Other Study ID Numbers:||
97623 ( Other Identifier: Stanford University Alternate IRB Approval Number )
BMT185 ( Other Identifier: OnCore )
|First Posted:||June 4, 2007 Key Record Dates|
|Results First Posted:||February 14, 2018|
|Last Update Posted:||February 14, 2018|
|Last Verified:||January 2018|
Neoplasms by Histologic Type
Immune System Diseases
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating